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1. Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory disease with potential disabling 
outcomes. Clinically, patients presented with inflammatory lower back pain, enthesis and 
alternated buttock pain (van der Linden & van der Heijde, 1998). Bernard Corner (1666-
1698) was the first physician who published the clinical features of AS in his medical thesis 
(Baker & Weisman, 2006). In the late 19th century, 3 independent physicians: Marie, 
Strupell, and Bechterew were able to describe the specific radiographic change in those 
patients by the help of the invention of radiology (Bywaters, 1983). But, still clinically, the 
boundary between AS and rheumatoid arthritis was unclear. Thanks to the discovery of 
rheumatoid factor which was strongly associated with rheumatoid arthritis, the distinction 
between these two arthritides became crystal clear. In those patients with inflammatory 
lower back pain and seronegative for rheumatoid factor, the diagnosis of ankylosing 
spondylitis became more popular in the early 1960 (Zeider et al., 2011). In 1963, American 
Rheumatism Association proposed a new nomenclature and classification for the rheumatic 
diseases. In this new edition, AS was specified as a complete different disease entity from 
rheumatoid arthritis (Blumberg et al., 1964). In addition to those different clinical 
characteristics, such as bone proliferation in enthesis site and sacroiliitis, in AS patients from 
those of patients with rheumatoid arthritis, AS is also known for its high association with 
HLA-B27. It has been known for more than 30 years since this association was discovered at 
1973 (Schlosstein, 1973; Brewerton et al., 1973), although afterward, researchers found 
several HLA antigens were associated with other diseases (Invernizzi, 2011; McElroy, 2011; 
Piga, 2011), the strongest of any HLA antigens associated with human disease is HLA-B27 
molecule. Hence, the roles of HLA-B27 in the pathogenesis and clinical manifestation of 
ankylosing spondylitis were among most frequent discussed topics in the past three 
decades. 
2. Structure, subtypes and epidemiology of HLA-B27 
HLA-B27 is one of the HLA class I molecules which are highly polymorphic and plays major 
role in protective immunity against intracellular parasites including virus and bacteria 
(Bjorkman et al., 1987). Traditionally, HLA class I molecule is considered to present peptide 
antigens to cytotoxic (CD8+) T cells. X-ray crystallographic studies revealed that extracellular 
structure of heavy chain of class I molecule contained three components: ┙-1, ┙-2 and ┙-3 
domains. ┙-1 and ┙-2 together with a ┚ pleated intervening sequence to form a peptide 
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binding groove. ┙-3 domain is the membrane-proximal  portion of the heavy chain which 
interact with CD8 of cytotoxic T cells. Besides binding peptides, class I molecule must associate 
non-covalently with beta2-microglobulin to form the tri-molecule complex on the cell surface.  
In lack of any one of these molecules, the molecular stability of this tri-molecule complex will 
be weak and easy to be degraded (Natarajan et al., 1999; Madden et al., 1991). Through their 
different amino acid compositions at binding groove, different HLA class I antigens has their 
own specific selectivity of binding peptides (Madden et al., 1992). In addition, to the selectivity of 
binding peptides, differences in the amino acid composition also influence the strength of 
association between heavy chain and beta2-microglobulin. (David, 1997). 
HLA-B27 is a unique HLA class I molecule, not only because of its high association with AS 
but also has characteristically different amino acid composition from other class I molecules. 
In brief, there are two important characteristic structures which are different from others: 
the presence of B pocket and the free thiol group of Cys67 (Madden, 1995; Powis et al, 2009). 
In the presence of B pocket in the binding groove, B27 anchoring peptides had a very 
specific P2 residue: arginine. Free thiol Cys67 residue made B27 molecule easy to form 
homodimer in the extracellular domain which has great impact on its physiological role 
(Allen et al, 1999). There is an astonishing distribution of HLA-B27 gene among world 
population, with highest prevalence in northern territory of the earth, Eskimos and Native 
American in the circumpolar area and north Canada were known for their high carrier rate 
and some of the world's highest prevalence rates of spondyloarthropathies are described in 
these groups (Peschken & Esdaile, 1999; Boyer et al., 1997). It was shown that the 
distribution of HLA-B27 had a tendency of a decreasing north-south gradient of prevalence 
and was speculated that the peculiar geographic distribution of HLA-B27 might reflect a 
genetic selection for better survival from microbial infection (Piazza et al., 1980) (Figure 1).  
 
Fig. 1. The structure of HLA-B27 molecule. E45 and C67 are shared between all predisposing 
alleles. The presence of unpaired C67 made B27 molecule easy to form homodimers. In 
addition, the presence of H9 in the floor of ┚ pleated sheet is critical for the stability of the 
heavy chain/┚2-microglobulin complex. 
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Till July 2011, 82 HLA-B27 subtypes were described based on nucleotide differences 
(International IMunoGene Tics information system [IMGT], 2011). Most nucleotide changes 
locate at exons 2 and 3 which encode the ┙-1 and ┙-2 domains.  HLA-B*27:05 is the most 
prevalent subtype and present in almost every population in the world. It was thought that 
HLA-B*27:05 was the ancestor subtype, all other subtypes could have evolved from HLA-
B*27:05 by point mutation (B*27:03), reciprocal recombination (B*27:07, B*27:09) and gene 
conversion (B*27:01, B*27:02, B*27:04, B*27:06). Following the ethnic migration and genetic 
evolution, HLA-B27 evolved into three ancestral pathways. Each pathway developed into a 
specific pattern. The first pattern was characterized by amino acid substitutions in the ┙-1 
domain. HLA-B*27:02 was the most frequent allele, followed by HLA-B*27:03. This pattern 
is found largely in Africa, Middle Eastern and European groups. The second pattern 
contains a constant substitution at ┙-1 domain and variable substitutions at ┙-2 domain. 
HLA-B27:04 was the most prevalent subtype. This pattern is largely found in Eastern Asian 
such as Chinese, Thai and Korean. The third pattern contains a similar ┙-1 domain as HLA-
B*27:05 and variable substitution at ┙-2 domain. In which, HLA-B*27:07 is the most 
prevalent subtype. This pattern is largely found in Middle East, but also in Turkey and 
Greece (Reveille & Maganti, 2009) (Figure 2). 
 
Fig. 2. Phylogenetic trees for the most common HLA-B27 subtypes (Adapted and modified 
from Blanco-Gelaz et al., 2001). 
It is interesting to note that not all subtypes are associated with AS. In addition to B*27:05, 
most alleles such as B*27:01, B*27:02, B*27:03, B*27:04, B*27:10, B*27:13, B*27:14, B*27:15 are 
documented to be associated with ankylosing spondylitis (Taurog, 2007). In Chinese 
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population, B*27:04 seemed to play major role in the pathogenesis of AS. Meta-analysis 
results showed a positive association between B*27:04 and susceptibility to AS in Han 
population (Zang et al., 2011). Also in the Taiwanese population, susceptibility to AS was 
determined by the presence of HLA-B*27:04 (Hou et al., 2007).  In contrast, two subtypes, 
B*27:06 and B*27:09 have been reported not to be associated with AS and even considered to 
play a protective role. B*27:06 is a common subtype in countries such as Indonesia, 
Singapore and Thailand. In Singapore Chinese, B*27:06 had a significant negative 
association with AS (Ren et al., 1997). The same result also was reported from Taiwanese 
patients (Chen et al., 2002). Similarly, B*27:09, a rare subtype primarily found in Sardinia 
island and southern Italy, was found to have negative association with AS (Fiorillo et al., 
2003). In addition to B*27:06 and B*27:09, other HLA-B27 alleles such as B*27:08 in 
Venezuela and B*27:07 in Cyprus were claimed not to be associated with AS (Armas et al., 
1999). But these results are not universal, in other populations the same alleles have been 
found in AS patients (Cipriani et al., 2003; Varnavidou-Nicolaidou et al., 2004; Paladini et al., 
2005). (Table 1) 
 
B27 subtype Ethnic distribution Association with AS 
B*27:05 
B*27:02 
B*27:03 
B*27:04 
B*27:06 
B*27:07 
B*27:08 
B*27:09 
 
Most ethnic groups 
Caucasians, Central American,  American Indians 
Africans 
Asians 
Asians 
Caucasians, Cyprus, middle east 
Caucasians, Central Americans 
Sardinian, Italy 
＋ 
＋ 
＋ 
＋ 
－ 
＋ 
＋ 
－ 
 
Table 1. The ethnic distribution and ankylosing spondylitis association of most frequent 
subtypes of HLA-B27. 
3. Hypotheses of the role of HLA-B27 in the pathogenesis of ankylosing 
spondylitis 
Since the discovery of the high association of HLA-B27 with AS, models have been 
proposed to explain the role of B27 in the pathogenesis of AS. Several aspects of research 
were made including epidemiology studies, analysis of molecular structure, transgenic 
animal models and analysis of environmental factors. Using these tools, during the past 
three decades, several hypotheses had been raised successfully to explain some aspects of 
this association, but still, like the story of blind men and elephant, each hypothesis touch 
tangentially different appendages of the animal. The correct description fit all aspects of the 
elephant remained unsolved.   
In most population, B27 carry-rate was more than 80%in patients with ankylosing 
spondylitis.  However, B27 carry-rate in patients with ankylosing spondylitis was less than 
50% in some areas. For example, among African Americans, 50% of patients with ankylosing 
spondylitis possess HLA-B27 (Akkoc & Khan, 2006). Focus had been put on the effect and 
level of gene expression of B27 on disease presentation.  It was reported that disease 
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developed earlier in patients who were HLA-B27+ than those HLA-B27- (Wu et al., 2009). B-
27+ patients had higher incidence of anterior uveitis and hip joint involvement (Khan et al., 
1977; Feldtkeller et al., 2003).  The level of HLA-B27 mRNA had been claimed to be 
correlated with clinical disease activity in Chinese patients (Liu, 2006). It is interesting to 
find that in animal study, the copy number of HLA-B27 genes seemed to be a critical factor 
in determining the expression of a arthritis phenotype (Mammer et al, 1990). However, the 
effect of B27 homozygosity on the risk of disease development was controversial (van der 
Linden et al., 1984; Kim et al., 2009; Jaakkola et al., 2006). On the other hand, only a small   
percentage of B27-carriers developed AS. Twin studies suggest that susceptibility to AS is 
more than 90% inherited. HLA-B27 accounts for more than 50 % of this inheritance (Brown 
et al., 2000; Brown et al., 1997).  Other genes must be involved in the disease development. A 
genome-wide study identified several other candidate genes such as ERAP1, IL-23R, IL1R2, 
ANTXR2, TNFSF15, TNFR1 and TRADD (Australo-Anglo-American Spondyloarthritis 
consortium [TSAC]; Reveille et al., 2010; Wellcome Trust Case Control Consortium [TASC]; 
Burton et al., 2010). Many of these candidate genes are hot topics for research recently 
(Campbell et al., 2011; Chen et al., 2011; Layh-Schmitt & Colbert, 2008; Brown, 2010).  
According to the above finding, theories of the disease pathogenesis were proposed. 
Hypotheses including molecular mimicry, arthritogenic peptide, free heavy chain and 
unfolded protein response were considered main streams of hypotheses.  
3.1 Theory of molecular mimicry and arthritogenic peptides 
A striking finding of the similarity of 6 consecutive amino acids of HLA-B27 to 6 consecutive 
amino acids of nitrogenase from Klebsiella pneumonia made researchers to propose that after 
the microbial infection, our immune system mis-recognized self-antigens as a target and 
launched an autoimmune response (Schwimmbeck & Oldstone, 1998). A Finnish group also 
identified that two bacterial proteins shared homology with HLA-B27, namely  YadA 
(Yersinia adhesin) and OmpH, outer surface proteins of Yersinia and Salmonella, 
respectively (Lahesmaa et al., 1991). Further support of this hypothesis is the finding that 
HLA class II antigen associated with rheumatoid arthritis shared the same amino acid 
sequences with some viral antigens ( Albani & Carson, 1996 ). Data from serologic studies 
also indicated that patients with AS had high incidence of antibodies against microbial 
pathogens (Ewing et al., 1990). This study indicate that AS patient sera contain antibodies 
which were reactive to K. pneumoniae nitrogenase peptides and HLA B27.1 peptides, and 
that there are at least two epitopes in the alpha 1 domain at the groove region, that are 
autoantigenic. However, not all reports are consistent, later reports did not support the 
finding of antibodies against self-antigens in patients with AS (de Vries et al., 1992).   
As mentioned before, the unique amino acid composition, especially in the peptide –binding 
groove, made B27 molecule distinct. The presence of B pocket fits only arginine inside. This 
finding together with the knowledge of highly polymorphism of B27 alleles which were 
differentially associated with AS pave a new way to search for the presence of arthritogenic 
peptides with the ability to provoke arthritis. All these alleles differed from each other by only 
one or few amino acid changes, but interestingly, the association with AS were quite different. 
Most HLA-B27 alleles are found at a very low frequency, their association with AS are largely 
unknown. B*27:05 is an ancestral type and associated with AS in almost every population in 
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the world. B*27:04 is very prevalent in Asian country and also is thought to make individual 
susceptible to AS. On the contrary, B*27:03, B*27:06 and B*27:09 were considered to play a 
protective role. Rare incidence of these allele-carriers developed AS.  B*27:03 was initially 
thought not to be associated with AS and only was prevalent in Black African population 
where B*27:05 is also not associated with AS (Hill et al., 1991). Certainly, other genes might be 
involved in the pathogenesis. Recently, AS patients possessing B*27:03 were found (Reveille et 
al., 2000).  B*27:09 were found in healthy inhabitants of Sardinian island but not in patients, 
who only carry B*27:05. Although a case of AS possess B*27:09 together with B*14:03, another 
AS-associated allele in black Africans reported (Cauli et al., 2007). The amino acid sequence of 
B*27:09 differed from that of B*27:05 only in residue 116 (His vs Asp) .(de Castro, 2009) . Self-
peptide pVIPR binds to B*27:05 in dual conformation but only one conventional form can be 
bound to B*27:09 ( Hulsmeyer M et al., 2004). This different binding link might provoke 
different T cell response. B*27:06 is found mainly in Southeastern Asia among healthy control, 
while other B27 alleles were associated with AS. B*27:03 differs from B*27:05 by the Y59H 
change located in the A pocket. B*27:04 and B*27:06 are closely related differ only by two 
amino acid changes, namely H114D and D116Y.  Different amino acid sequences in the 
binding groove will change the polar-nonpolar interaction of heavy chain with peptides, hence 
causes different peptides anchoring to the groove. It was postulated that some disease-causing 
alleles of HLA-B27 selectively bound arthritogenic peptides derived from several intracellular 
parasites which were claimed to be triggering agents in reactive arthritis. Even more, some 
investigators found that peptides derived from self antigen, including peptide from HLA-B27 
itself and cartilage were found to trigger CD8+ T cell response (Kuhne et al., 2009; Atagunduz 
et al., 2005). Three self peptides derived from cartilage/bone proteins showed homology to 
sequence of protein from arthritogenic bacteria. One of them, peptide PRGLLAWISR derived 
from chondoitin sulfate N-acetygalatosaminyltransferase 1 shared 8 amino acids with FhuB 
protein from Yersinia Enterocolitica and 7 amino acids with intracellular attenuator protein A 
from Salmonella Typhimurium (Dror LB et al., 2010). The presence of self peptide in the HLA 
binding groove with homologous sequence from arthritogenic bacteria forms the cornerstone 
of molecular mimicry. It is interesting to note that in addition to HLA-B27, HLA-B39 had 
similar B pocket was found to be associated with ankylosing spondylitis in those who were 
HLA-B27 negative. It was considered to harbor same peptide repertoire with HLA-B27 
(Yamaguchi et al, 1995). Another observation is that HLA-B*14:03 is a major MHC molecule 
associated with AS in Africa, it differs from HLA-B*27:05 at 18 positions and shares only 3-5% 
peptide repertoires (Lopez-Larrea et al., 2002). Two important papers showed that CD8+ 
cytotoxic T cells are not essential for the arthritis to develop. In these observations, May et al 
use monoclonal antibody to deplete CD8+ T cells from peripheral circulation, however, 
arthritis and colitis still develop in the HLA-B27 transgenic rat (May et al.,2003). In addition, 
the same conclusion was obtained by the chemical deletion of CD8a gene expression which 
eliminated CD8+ T cells from peripheral blood (Taurog et al, 2009). The other observation 
revealed that CD4+ T cells, when transferred to athymic nude rat which had high level of 
HLA-B27/h2m expression in the bone marrow, developed arthritis (Taurog et al., 1999). 
3.2 Free heavy chain theory 
Another models focus on the molecular stability of tri-molecular complex indicating that 
due to unique amino acid composition at interface between HLA-B27 and beta2-
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microglobulin, the tri-molecular complex is not stable enough. Only HLA-B27 was found to 
be able to express as free form. Amino acid residue 9 in the floor of ┚ pleated sheet is critical 
for the stability of the heavy chain/┚2-microglobulin complex. All the HLA-B27 subtypes 
contain histidine at this site, interestingly, two other classs I molecules, HLA-B73 and HLA-
B40, which had been reported in a few cases of spondyloarthropathies, were found to have 
histidine at amino acid residue 9 (David, 1997). Histidine at this position was claimed to 
weaken the non-covalent interaction between heavy chain and ┚2-microglobulin. The 
unstable structure made HLA-B27 dissociate from beta2-microglobulin and presented as 
free form on the cell surface. It was proposed that free HLA-B27 bound different peptides 
from those stable forms. Higher percentage of free heavy chain-carrying monocytes was 
found in the peripheral blood and synovial fluid in patients with AS compared to normal 
population. The level of free heavy is correlated with sedimentation rate (Tsai et al., 2002). In 
addition, as mentioned before, in the presence of unpaired Cys67 free heavy chains have 
been shown to form homodimer. Expression of heavy chain homodimer on the surface of 
cell lines and AS patients’ peripheral blood mononuclear cells was observed. (Kollnberger et 
al., 2002) 
This HC homodimer was found to bind to NK inhibitory receptors KIR3DL1 and KIR3DL2 
and LILRA1, LILRB2 alleles on the surface of NK, T and B cells. Patients with ankylosing 
spondylitis have higher level of Th17 cells expressing KIR3DL2 and responsive to B27 HC 
homodimer (Bowness et al., 2011).  This hypothesis postulates that through this interaction, 
NK cells, B cells and T cells were activated to induce the inflammatory reaction. 
3.3 Unfolded protein response theory 
In the last decade, another new theory was proposed calling ”unfolded protein response”. 
In this theory, researcher proposed that due to its unique structure, i.e.; the presence of B 
pocket and free form, HLA-B27 molecule is not properly folded in the endoplasmic 
reticulum. The accumulation of unfolded proteins in the endoplasmic reticulum induced 
stress reaction in the organelle and hence triggered inflammatory response. Most evidences 
came from animal study. Khare et al found high incidence of joint inflammation and 
ankylosis when HLA-B27 was transgenic into ┚2-microglobulin deficient mice (Khare et al., 
1995). Later, investigator found a deficiency in class I molecule expression either due lack of 
peptides (TAP-/TAP-) or ┚2-microglobulin was able to induce spontaneous inflammatory 
joint disease (Kinsbury et al, 2000).  In animal study, transgenic rats were found to have 
increased IL-23 secretion when unfolded protein response was triggered by B27 molecule in 
the presence of pattern recognition receptor agonist (Colbert et al., 2010). This finding 
reminds us that IL-23R was found to be a susceptibility gene from genome-wide scan. 
Another observation from genome-wide scan shows that one of the peptide-trimming 
peptidase: ERAP1 is associated with AS. Defect in the function of ERAP1 might delay the 
folding process of HLA class I molecules (Evans et al., 2011).  Patients with AS were found 
to have high level of chaperon proteins which were related to the folding process of class I 
molecules in their macrophage derived from peripheral joint (Dong et al., 2002). 
4. Conclusion 
In conclusion, the high association of HLA-B27 with ankylosing spondylitis paved the path 
to the resolution of pathogenesis of this disease. Identification of this important finding 
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might open ways to design new treatment modalities and prevent the occurrence of the 
disease. Evidence from both epidemiology and transgenic animal studies further widen our 
vision. Although none of the above theories can explain all the phenomena we observed 
before, newer data from genome-wide scan can further supplement the missing link. 
5. References 
Akkoc N, Khan MA. 2006. Epidemiology of ankylosing spondylitis and related 
spondyloarthropathies.  In Ankylosing Spondylitis and the Spondyloarthropathies: 
A Companion to Rheumatology. Weisman MH, Reveille JDvan der Heijde D. pp 
117-131, Mosby-Elservier London. 
Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of 
rheumatoid arthritis. Immunology today 1996;17(10):466-70 
Allen RL, O’Callagran CA, McMichael AJ, et al. Cutting edege. HLA-B27 can form a novel 
beta2-microglobulin-free heavy chain homodimer structure. J Immunol 
1999;162:5045-8. 
Arms JB, Gonzalez S, Martinez-Borra J et al.. Susceptibility of ankylosing spondylitis is 
independent of the BW4 and BW6 epitopes of the HLA-B27 alleles. Tissue 
antigens.1999;53(3):237-43. 
Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J. 
Australo-Anglo-American Spndyloarthritis consortium (TASC); Reveille, L. D. et al, 
Genomewide association study of ankylosing spondylitis identifies non-MHC 
susceptibility loci. Nat. Genet. 42,123-127(2010).  
Baker SA, Weisman MH. Introduction to unifying concepts of spondyloarthropathy, 
including historical aspects of the disease. In:Weisman M, van der Heijde D, 
Reveille J, editors. Ankylosing spondylitis and the spondyloarthropathies. 
Philadelphia, PA: Mosby Elsevier;2006. Pp1-6. 
Bjorkman PJ, Saper MA, Samraoui B, et al. Structure of the human class I histocompatibility 
antigen  HLA-A2. Nature 1987;329:506-12 
Blanco-Gelaz MA, Lopez-Vazquez A, Garcia-Fernandez S, et al. Genetic variability, 
molecular evolution, and geographic diversity of HLA-B27. Human Immunol 
2001;62:1042-50. 
Blumberg B, Bunium JJ, Calkins E, et al. ARA nomenclature and classification of arthritis 
and rheumatism. Arthritis Rheum 1964;7:93-7.  
Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+ and responsive to HLA-
B27 homodimers are increased in ankylosing spondylitis. J Immunol 2011;186:2672-
80. 
Boyer GS, Templin DW, Bowler A, Lawrence RC, Heyse SP, Everett DF, Cornoni-Huntley 
JC, Goring WP. Class I HLA antigens in spondyloarthropathy: observations in 
Alaskan Eskimo patients and controls. J Rheumatol. 1997 Mar;24(3):500-6. 
Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DCO, Sturrock RD. Ankylosing 
spondylitis and HLA-B27. Lancet 1973:1;904-7. 
Brown MA, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, 
and the environment. Arthritis Rheum. 1997;40:1823-28. 
Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheum 2010;22:126-32. 
Brown, M.A., Lavel, S. H., Brophy, S. & Calin, A. Recurrence risk modeling of the genetic 
susceptibility to ankylosing spondylitis. Ann. Rheum. Dis.59, 883-886(2000). 
www.intechopen.com
 
HLA-B27 and Ankylosing Spondylitis 
 
81 
Bywaters EGL. Histological perspectives in the etiology of ankylosing spondylitis. Brit J 
Rheumatol 1983;22 (suppl 2):1-4. 
Campbell EC, Fettke F, Bhat S, Morley KD, Powis SJ. Expression of MHC class I dimers and 
ERAP1 in an ankylosing spondylitis patient cohort. Immunology. 2011 
Jul;133(3):379-85.  
Cauli A, Vacca A, Mameli A et al. A Sardinian patient with ankylosing spondylitis and 
HLA-B*2709 co-occurring with HLA-B1403. Arthritis Rheum 2007:56;2807-9. 
Chen IH, Yang KL, Lee A, Huang HH, Lin PY, Lee TD. Low frequency of HLA- B*2706 in 
Taiwanese patients with ankylosing spondylitis. Eur J Immunogenet. 2002 
Oct;29(5):435-8. 
Chen R, Yao L, Meng T, Xu W. The association between seven ERAP1 polymorphisms and 
ankylosing spondylitis susceptibility: a meta-analysis involving 8,530 cases and 
12,449 controls. Rheumatol Int. 2011 Jan 13. [Epub ahead of print]  
Cipriani A, Rivera S, Hassanhi M, Marquez G, Hernadez R, Villalobos C, et al. HLA-B27 
subtypes determination in patients with ankylosing spondylitis from Zulia, 
Venezuela. Human Immunol 2003;64:745-9. 
Colbert RA, Delay ML, Klenk EI et al. From HLA-B27 to spondyloarthritis: a journey 
through the ER. Immunol Rev 2010;233:181-202 
David CS. The mystery of HLA-B27 and disease. Immunogenetics 1997;46:73-7 
de Castro JA. HLA-B27-bound peptide repertoires: their nature, origin and pathogenetic 
relevance. Adv Exp Med Biol. 2009;649:196-209 
de Vries DD, Dekker-Saeys AJ, Gyodi E, Bohm U, Ivanyi P. Absence of autoantibodies to 
peptides shared by HLA-B27.5 and Klebsiella pneumoniae nitrogenase in serum 
samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's 
syndrome. Ann Rheum Dis 1992;51:783-9. 
Dong, W. et al. Upregulation of 78-kDa glucose-regulated protein in macrophages in 
peripheral joints of active ankylosing spondylitis. Scand. J. Rheunatol. 2002;29: 
2159-2164. 
Dror LB, Barnea E, Beer I et al. The HLA-B2705 peptidome. Arthritis Rheum 2010;62:420-9. 
Evans DM, Spencer CC, Pointon JJ et al.. Interaction between ERAP1 and HLA-B27 in 
ankylosing spondylitis implicates peptide handling in the mechanism of HLA-B27 
in disease susceptibility. Nature genet .2011;43(8):761-7. 
Ewing C, Ebringer R, Tribbick G, Geysen HM. Antibody activity in ankylosing spondylitis 
sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), 
and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 
181-199). J Exp Med. 1990 May 1;171(5):1635-47.  
Feldtkeller E, Khan MA, van der Linden et al.. Age at disease onset and diagnosis delay in 
HLA-B27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int 
2003;23:61-66. 
Fiorillo MT, Cauli A, Carcassi C, Bitti PP, Vacca A, Passiu G, Bettosini F, Mathieu A, 
Sorrentino R. Two distinctive HLA haplotypes harbor the B27 alleles negatively or 
positively associated with ankylosing spondylitis in Sardinia: implications for 
disease pathogenesis. Arthritis Rheum 2003;48:1385-9. 
Hammer RF, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in 
transgenic rat expressing HLA-B27 and human 2m: an animal model of HLA-B27-
associated human disorder. Cell 1990,63:1099-1112.  
www.intechopen.com
 
Clinical and Molecular Advances in Ankylosing Spondylitis 
 
82
Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Greenwood BM, McMichael AJ. HLA 
class I typing by PCR: HLA-B27 and an African B27 subtype. Lancet. 1991 Mar 
16;337(8742):640-2. 
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing 
spondylitis. Arthritis Rheum. 2005 Mar;52(3):892-901 
Hou TY, Chen HC, Chen CH, Chang DM, Liu FC, Lai JH. Usefulness of human leucocyte 
antigen-B27 subtypes in predicting ankylosing spondylitis: Taiwan experience. 
Intern Med J. 2007 Nov;37(11):749-52. 
Hulsmeyer M, Fiorillo MT, Bettosini F et al. Dual, HLA-B27 subtype-dependent 
conformation of a self-peptide. J Exp Med 2004;199:271-81. 
IMGT/HLA database allele search tool [Internet. Accessed July 21. 2011] Available 
from:http://www.ei.ac.uk/cgi-bin/imgt/hla/allele.cgi. 
Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: An old story now 
reviving. Hepatology. 2011 May 11. [Epub ahead of print]  
Jaakkola E, Herzberg I, Laiho K, Barnardo MC, Pointon JJ, Kauppi M, Kaarela K, 
Tuomilehto-Wolf E, Tuomilehto J, Wordsworth BP, Brown MA. Finnish HLA 
studies confirm the increased risk conferred by HLA-B27 homozygosity in 
ankylosing spondylitis. Ann Rheum Dis. 2006 Jun;65(6):775-80. 
Khan MA, Kushner I, Braun WE. Comparison of clinical features in HLA-B27 positive and 
negative patients with ankylosing spondylitis. Arthritis Rheum 1977;20:909-912. 
Khare SD, Luthra HS, David CS. Spontaneous inflammatory arthritis in HLA-B27 transgenic 
mice lacking ┚2-microglobulin: a model of human spondyloarthropathies. J Exp 
Med 1995;182:1153-8 
Kim TJ, Na KS, Lee HJ. Lee B, Kim TH. HLA-B27 homozygosity has no influence on clinical 
manifestations and functional disability in ankylosing spondylitis. Clin Exp 
Rheumatol 2009:27:574-9.  
Kinsbury DJ, Mear JP, Witte DP. Development of spontaneous arthritis in ┚2-microglobulin-
deficient mice without expression off HLA-B27: association with deficieny of 
endogenous major histocompatibility complex I expression. Arthritis Rheum 
2000;43:2290-6. 
Kollnberger S, Bird L, Sun MY, Retiere C, Braud VM, McMichael A, et al. Cell-surface 
expression and immune receptor recognition of HLA-B27 homodimers. Arthritis 
Rheum 2002;46:2972-82. 
Kuhne M, Erben U, Schulze-Tanzil G, Köhler D, Wu P, Richter FJ, John T, Radbruch A, 
Sieper J, Appel H. HLA-B27-restricted antigen presentation by human 
chondrocytes to CD8+ T cells: potential contribution to local immunopathologic 
processes in ankylosing spondylitis. Arthritis Rheum. 2009 Jun;60(6):1635-46 
Lahesmaa R, Skurnik M, Vaara M, Leirisalo-Repo M, Nissilä M, Granfors K, Toivanen P. 
Molecular mimickry between HLA B27 and Yersinia, Salmonella, Shigella and 
Klebsiella within the same region of HLA alpha 1-helix. Clin Exp Immunol. 1991 
Dec;86(3):399-404. 
Layh-Schmitt, G. & Colbert, R. A. The interleukin-23/interlukin-17 axis in spondyloarthritis.  
Curr. Opon. Rheunatol. 20,392-397(2008).  
Liu SQ, Yu HC, Gong YZ, Lai NS. Quantitative measurement of HLA-B27 mRNA in patients 
with ankylosing spondylitis-correlation with clinical activity. J Rheumatol 
2006;33:1128-32. 
www.intechopen.com
 
HLA-B27 and Ankylosing Spondylitis 
 
83 
Lopez-Larrea C, Mijivawa M, Gonzalez S et al. Association of ankylosing spondylitis with 
HLA-B1403 in a western African population. Arthritis Rheum 2002;46:2968-71. 
Madden DR, Gorge JC, Strominger JL, et al. The structure of HLA-B27 reveals nonamer self-
peptides bound in a extended conformation. Nature 1991;352:321-5. 
Madden DR, Gorge JC, Strominger JL, et al. The three-dimentional structure of HLA-B27 at 
2.1 Å resolution suggest a general mechanism for the tight peptide binding to MHC 
Cell 1992;70:1035-44. 
Madden DR. The three-dimensional structure of peptide-MHC complexes. Ann Rev 
Immunol 1995;13:587-622. 
May E, et al. CD8 T cells are not essential to the pathogenesis of arthritis or colitis in 
HLA-B27 transgenic rats. J Immunol 2003;170:1099-1105.  
McElroy JP, Oksenberg JR. Multiple sclerosis genetics 2010. Neurol Clin. 2011 May;29(2):219-
31 
Natarajan K, Li H, Mariuzza RA, et al. MHC class I molecule structure and function. Rev 
Immunogenet 1999:1:32-46. 
Paladini F, Taccari E, Fiorillo MT, Cauli A, Passiu G, Mathieu A, et al. Distribution of HLA-
B27 subtypes in Sardinia and Continental Italy and their association with 
spondyloarthropathies. Arthritis Rheum 2005;52:3319-21. 
Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. 
Semin Arthritis Rheum. 1999 Jun;28(6):368-91. 
Piazza A, Menozzi P, Cavalli-Sfprza LL. The HLA-A,B gene frequencies in the world: 
migration or selection? Hum Immunol 1980;1:297-304. 
Piga M, Mathieu A. Genetic susceptibility to Behcet's disease: role of genes belonging to the 
MHC region. Rheumatology (Oxford). 2011 Feb;50(2):299-310. 
Powis SJ, Santos SG, Antoniou AN. Biochemical features of HLA-B27 and antigen 
processing. Adv Exp Med Biol. 2009;649:210-6 
Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. Possible protective role of HLA- 
B*2706 for ankylosing spondylitis. Tissue Antigens. 1997 Jan;49(1):67-9. 
Reveille JD, Inman R, Khan M, et al. Family studies in ankylosing spondylitis: microsatellite 
analysis of 55 concordant sib pairs. J Rheumatol 2000;27:5. 
Reveille JD, Maganti RM. Subtypes of HLA-B27: history and implications in the 
pathogenesis of ankylosing spondylitis. Adv Exp Med Biol 2009;649:159-76.  
Schlosstein L, Terasaki PI, Bluestone R, Pearson CM.High association of an HL-A antigen, 
W27, with ankyloing spondylitis. N Engl J Med 1973:288:704-6. 
Schwimmbeck PL, Oldstone MB. Molecular mimicry between human leukocyte antigen B27 
and Klebsiella. Consequences for spondyloarthropathies. Am J Med. 1988 Dec 
23;85(6A):51-3.  
Taurog  JD et al. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev 
1999;169:209-223.  
Taurog JD. The mystery of HLA-B27: if it isn’t one thing, It’s another. Arthritis Rheum 
2007:56:2478-81. 
Taurog JD et al. Spondyloarthritis in HLA-B27/human beta2-microglobulin-transgenic rats 
is not prevented by lack of CD*. Arthritis Rheum 2009;60:1977-84.  
Tsai WC, Chen CJ, Yen JH et al.. Free HLA class I heavy chain-carrying monocytes – a 
potential role in the pathogenesis of spondyloarthropathies. J Rheumatol 
2002;29:966-72. 
www.intechopen.com
 
Clinical and Molecular Advances in Ankylosing Spondylitis 
 
84
Van der Linden SM, Valkenburg HA, de Jongh BM, Catshe risk of developing ankylosing 
spondylitis in HLA-B27 positive individuals: a comparison of relatives of 
spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9. 
Van der Linden S, van der Heijde D. Ankylosing spondylitis, clinical features. Rheum Dis 
Clin North Am 1998;24:663-76. 
Varnavidou-Nicolaidou A, Karpasitou K, Georgiou D, Stylianou G, Kkkoftou A, Michalis C, 
et al. HLA-B27 in the Greek Cypriot population: distribution of subtypes in patients 
with ankylosing spondylitis and other HLA-B27-related diseases. The possible 
protective role of B*2707. Human Immunol 2004;65:1451-4. 
Wellcome Trust Case Control Consortium; (TASC); Burton, P. R. et al. Association scan of 
14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. 
Nat. Genet, 39, 1329-1337(2007). 
Wu Z, Lin Z, Wei Q, Gu J. Clinical features of ankylosing spondylitis may correlate with 
HLA-B27 polymorphism. Rheumatol Int 2009;29:389-92. 
Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, Yoshinoya S, Juji T, 
Ito K. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and 
pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a 
role of the peptide-anchoring B pocket. Arthritis Rheum 1995;38:1672-7. 
Zeider H, Calin A, Amor B. A historical perspective of the spondyloarthritis. Curr Opin 
Rheumatol 2011;23:327-33. 
Zhang L, Liu JL, Zhang YJ, Wang H. Association between HLA-B*27 polymorphisms and 
ankylosing spondylitis in Han populations: a meta-analysis. Clin Exp Rheumatol. 
2011 Mar-Apr;29(2):285-92. 
www.intechopen.com
Clinical and Molecular Advances in Ankylosing Spondylitis
Edited by Dr. Jacome Bruges-Armas
ISBN 978-953-51-0137-6
Hard cover, 164 pages
Publisher InTech
Published online 22, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The first section of the book entitled Clinical and Molecular Advances in Ankylosing Spondylitis is a review of
the clinical manifestations of Ankylosing Spondylitis (AS) and Spondyloarthritis (SpA). The book includes
chapters on Bone Mineral Density measurements, two chapters on the temporomandibular joints, axial
fractures, clinical manifestations, diagnosis, and treatment. Molecular genetics and immune response are
analyzed in the second section of the book; information on HLA-B*27, other MHC genes and the immune
response of AS patients to bacteria is reviewed and updated. Two chapters are dedicated to recent
information on non-MHC genes in AS susceptibility, and to new data on disease pathways generated from
gene expression studies on peripheral blood.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Wen-Chan Tsai (2012). HLA-B27 and Ankylosing Spondylitis, Clinical and Molecular Advances in Ankylosing
Spondylitis, Dr. Jacome Bruges-Armas (Ed.), ISBN: 978-953-51-0137-6, InTech, Available from:
http://www.intechopen.com/books/clinical-and-molecular-advances-in-ankylosing-spondylitis/hla-b27-and-
ankylosing-spondylitis
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
